# Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

> **NCT05627752** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Zhongnan Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Prostate Cancer
- Castrate Resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide 40 MG
- **DRUG:** Docetaxel injection

## Key facts

- **NCT ID:** NCT05627752
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-06-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05627752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05627752, "Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05627752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*